KAZIA THERAPEUTICS LTD Logo

KAZIA THERAPEUTICS LTD

Oncology-focused biotech developing targeted therapies for cancers with high unmet needs.

KZIA | US

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
THREE INTERNATIONAL TOWERS LEVEL 24,, 2000 SYDNEY NSW

Description

Kazia Therapeutics Ltd. is an oncology-focused biotechnology company engaged in the development of innovative drugs for cancer. The company's lead program is paxalisib, a small molecule inhibitor of the PI3K/AKT/mTOR pathway designed to cross the blood-brain barrier, which is being investigated for various forms of brain cancer. Its development pipeline also includes EVT801, a selective VEGFR3 inhibitor being studied for its potential to block the growth of blood and lymphatic vessels that support tumor growth. The company focuses on addressing cancers with high unmet medical needs through its portfolio of targeted therapies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2012-11-07 00:41
FORM 6K 2012 11 06 1
English 18.1 KB
2012-11-06 12:01
FORM 6K 2012 11 06
English 18.9 KB
2012-10-29 12:12
FORM 20F 2012 12 31
English 447.3 KB
2012-10-19 22:30
SCHEDULE 13D AMENDMENT NO. 6
English 16.5 KB
2012-10-16 02:21
FORM 6K 2012 10 11
English 36.0 KB
2012-10-02 14:10
FORM 6K 2012 10 02
English 16.7 KB
2012-09-25 00:39
FORM 6K 2012 09 24
English 15.6 KB
2012-08-24 14:02
FORM 6K 2012 08 30
English 503.3 KB
2012-08-17 13:55
FORM 6K 2012 08 17
English 16.0 KB
2012-08-09 01:30
FORM 6K 2012 08 09
English 19.7 KB
2012-07-27 15:16
FORM 6K 2012 07 27
English 35.3 KB
2012-06-28 14:03
FORM 6K 2102 06 29
English 16.5 KB
2012-06-06 01:52
FORM 6K 2012 06 06
English 18.4 KB
2012-06-05 00:40
FORM 6K 2012 06 04
English 18.8 KB
2012-05-30 15:22
FORM 6K 2012 05 29 1
English 9.3 KB

Automate Your Workflow. Get a real-time feed of all KAZIA THERAPEUTICS LTD filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for KAZIA THERAPEUTICS LTD

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for KAZIA THERAPEUTICS LTD via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

genOway Logo
Designs and develops genetically modified preclinical models for research.
France
ALGEN
Genprex, Inc. Logo
Clinical-stage gene therapy company developing therapies for cancer and diabetes.
United States of America
GNPX
Genxone Spolka Akcyjna Logo
A biotechnology company specializing in Next Generation Sequencing and medical diagnostics.
Poland
GX1
GeoVax Labs, Inc. Logo
Clinical-stage biotech developing vaccines and therapies for infectious diseases and cancer.
United States of America
GOVX
GH Research PLC Logo
Develops mebufotenin-based therapies for psychiatric and neurological disorders.
United States of America
GHRS
GI Innovation Inc. Logo
Researches and develops protein-based drugs for immuno-oncology and immunology.
South Korea
358570
Ginkgo Bioworks Holdings, Inc. Logo
Operates a horizontal platform for cell programming and synthetic biology.
United States of America
DNA
GRAIL, Inc. Logo
A healthcare company developing blood tests for multi-cancer early detection.
United States of America
GRAL
GT Biopharma, Inc. Logo
Clinical-stage immuno-oncology company developing therapies with its NK cell engager tech.
United States of America
GTBP
Guard Therapeutics International AB Logo
Clinical-stage biotech developing therapies to prevent acute kidney injury.
Sweden
GUARD

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.